Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors

Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic colorectal cancer. Although often considered inte...

Full description

Bibliographic Details
Main Authors: Jesús García-Foncillas, Yu Sunakawa, Dan Aderka, Zev Wainberg, Philippe Ronga, Pauline Witzler, Sebastian Stintzing
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
cetuximab
panitumumab
FOLFOX
FOLFIRI
antibody-dependent cell-mediated cytotoxicity
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00849/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00849/full

Similar Items